Connect with us

Technology

Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results

Published

on

LAV321demonstrated strong results in its third consecutive year of field trials in Europe

REHOVOT, Israel, Nov. 19, 2024 /PRNewswire/ — Lavie Bio Ltd., a leading ag-biologicals company and subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced significant progress in the development of its LAV321 bio-fungicide, targeting downy mildew. Over three years of field trials across Europe, evaluating the efficacy of LAV321 in protecting crops from fungal diseases, LAV321 demonstrated an impressive average efficacy rate of 70% against downy mildew in grapes. These results lead to the decision to advance it to the last stage of product development toward commercialization.

 

 

 

Downy mildew is a damaging foliar disease of grapes, leading to yield losses of up to 75% in key growing areas[1]. The global fungicide market, valued at over $24.5 billion in 2024, is projected to grow to $33.27 billion by 2028, with a compound annual growth rate (CAGR) of 7.9%[2]. As public interest in environmentally friendly farming practices rises and concerns about fungal resistance to chemical solutions increase, ag-biologicals like LAV321 are emerging as preferred solutions to address these challenges and promote sustainable agriculture.

In addition to the field trials targeting downy mildew, during 2024 Lavie Bio also conducted trials evaluating LAV321 for the control of late blight in tomato. The trials demonstrated an average efficacy rate exceeding 60%, equivalent to commonly used copper products, which LAV321 is intended to substitute. Late blight is a key disease in management of tomato and potato crops, creating an estimated $6.7 billion in global damages annually[3].

LAV321 was discovered and optimized through Lavie Bio’s Biology Driven Design (BDD) platform, powered by Evogene’s MicroBoost AI tech-engine. It is designed to integrate seamlessly into farmers’ existing Integrated Pest Management (IPM) practices, enhancing productivity and sustainability while helping to prevent the development of resistance to conventional fungicides.

Amit Noam, Lavie Bio’s CEO, expressed his satisfaction with the announced advancement: “We are very pleased with LAV321’s performance over the last three years of our field trials, as well as in numerous trials conducted by several of our multinational partners. Our target of reaching 70% efficacy against downy mildew this year was successfully achieved, providing validation to our effective solution for key fruit and vegetable diseases, while fitting easily into current IPM practices. I am proud to announce that LAV321 has completed its development and is now entering the pre-commercial stage, with regulatory processes set to begin.”

About Lavie Bio Ltd.

Lavie Bio, a subsidiary of Evogene Ltd., aims to improve food quality, sustainability, and agriculture productivity through the introduction of microbiome-based ag-biological products. Lavie Bio utilizes a proprietary computational predictive platform, the BDD platform, powered by Evogene’s proprietary MicroBoost AI tech-engine, harnessing the power of big data, artificial intelligence, and advanced informatics, for the discovery, optimization and development of bio-stimulant and bio-pesticide products.
For more information, please visit www.lavie-bio.com.

About Evogene Ltd.

Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines – MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).

Evogene uses its tech-engines to develop products through subsidiaries and strategic partnerships. Evogene’s subsidiaries currently utilize the tech-engines to develop human microbiome-based therapeutics by Biomica, ag-biologicals by Lavie Bio, ag-chemicals by AgPlenus, medical cannabis products by Canonic and castor varieties, for the biofuel and other industries, by Casterra. 

For more information, please visit: www.evogene.com

Forward Looking Statements

This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “hopes” “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates”, “demonstrates” or words of similar meaning. For example, Evogene and its subsidiaries are using forward-looking statements in this press release when they discuss public interest in environmentally friendly solutions and the adoption of ag-biologicals like LAV321 as preferred solutions, the integration of farmers of LAV321 and successful achievement of regulatory approvals. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the current war between Israel and Hamas and any worsening of the situation in Israel such as further mobilizations or escalation in the northern border of Israel and those risk factors contained in Evogene’s reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Contact:
ir@evogene.com
Tel: +972-8-9311901

[1] Plasmopara viticola the Causal Agent of Downy Mildew of Grapevine: From Its Taxonomy to Disease Management, Kseniia Koledenkova et al. Frontiers in Microbiology, May 2022
[2] EINPresswire: Fungicides Market Growth Analysis With Investment Opportunities For 2024-2033
[3] https://www.ars.usda.gov/news-events/news/research-news/2021/wild-potatoes-tapped-for-late-blight-guard-duty/

Logo: https://mma.prnewswire.com/media/945133/lavie_bio.jpg
Logo: https://mma.prnewswire.com/media/1947468/Evogene.jpg

View original content:https://www.prnewswire.com/news-releases/lavie-bio-advances-its-bio-fungicide-lav321-targeting-downy-mildew-to-pre-commercial-stage-following-successful-2024-field-trial-results-302309731.html

SOURCE Lavie Bio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Stryker unveils Oculan Lighting Platform to enhance surgical visualization and illumination

Published

on

By

FLOWER MOUND, Texas, USA, Nov. 19, 2024 /PRNewswire/ — Stryker (NYSE: SYK), a global leader in medical technologies, unveiled the Oculan Lighting Platform, an innovative lighting solution designed to provide consistent, high-quality illumination, allowing surgeons to focus on delivering the highest standard of care.

In today’s operating rooms, where precision and accuracy are critical, even the smallest challenges may impact surgical outcomes – factors which may impede a surgeon’s ability to see clearly and work efficiently.

“The Oculan Lighting Platform was developed in response to real-world challenges faced by surgeons, as identified through extensive customer feedback,” said Caitlin Clark, vice president and general manager of Stryker’s Communications business. “This new solution is designed to improve the visualization experience, surgical performance and patient safety within the operating room.”

The Oculan Lighting Platform offers advanced features designed to enhance surgical precision and comfort:

Fly Eye technology within the optical architecture: This proprietary design ensures that instruments, hands, and the surgeon’s head do not create dim areas, providing even light distribution.

Consistent illumination: Allows surgeons to maintain a clear view and is designed to increase optical efficiency and reduce color ringing at the surgical site within procedures.

Auto lux and Microspot: Provides uniform brightness and pure white even in harder-to-reach areas such as a deep cavity or small incision procedures.

SHD Mode: Removal of perceived red is designed to improve contrast, tissue differentiation, and reduction of glare off instrumentation to improve the visual experience.

Heat minimization: Designed to produce less heat through heat dissipation, creating a cooler, more comfortable environment for lengthy surgeries.

Reduced glare and reflections: Helps surgeons stay focused and minimizes eye strain.

Ease of adoption: Suspension modularity allows for the Oculan Lighting Platform to be installed in operating rooms with existing Stryker surgical lights, causing minimal OR downtime.

“Clear visualization is one of the most critical aspects of surgical lighting,” said Dr. Shyamali Mallick Singhal, Chief Medical Officer of Apricity Health in California. “The ability to see clearly without shadows or dim spots is essential for precise work. The Oculan Lighting Platform excels in providing bright, even light in these hard-to-reach spaces, where surgeons need it most. Just as important are its enhanced contrast capabilities, which allow us to distinguish between different tissues and anatomical structures more easily, significantly improving our ability to identify critical details with greater accuracy and confidence. This level of visibility is essential for delivering safer, more efficient surgeries.”

Engineered for long-term performance, the Oculan Lighting Platform is designed to enhance functionality and durability. Its intuitive controls allow surgical teams to easily adjust settings to meet their specific needs. Emphasizing user-friendliness, the platform features multiple control points that streamline workflows and minimize disruptions. For more information about the Oculan Lighting Platform and Stryker’s full range of medical technologies, please visit here.

About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.

Media contact: 
Elizabeth Mortek
elizabeth@inprela.com
Inprela PR

View original content to download multimedia:https://www.prnewswire.com/news-releases/stryker-unveils-oculan-lighting-platform-to-enhance-surgical-visualization-and-illumination-302309452.html

SOURCE Stryker

Continue Reading

Technology

Trellis Launches Trellis AI to Revolutionize Trial Court Litigation

Published

on

By

Built on the industry’s largest US trial court database, Trellis AI delivers unparalleled insight and efficiency to legal teams

LOS ANGELES, Nov. 19, 2024 /PRNewswire/ — Today, Trellis launched Trellis AI, a powerful new legal productivity platform designed for the complex needs of trial court litigation. Built on Trellis’ industry-leading trial court data foundation—which is the most comprehensive database of its kind in the US—Trellis AI offers tools that empower legal teams to harness data and insights in transformative ways. By automating litigation tasks like motion drafting and case evaluations, Trellis AI transforms the way litigators approach case work with greater accuracy, efficiency, and strategic insight.

Trellis AI: A legal productivity platform tailored for trial court litigation, built on the leading trial court database

Trellis is an AI-driven legal research and insights platform offering access to the largest and most comprehensive US trial court database. This extensive database includes dockets, documents, rulings, judge, law firm, and company analytics, with unmatched coverage across states, counties, and courts.

Trellis AI leverages this extensive data foundation along with advanced language models to deliver precise insights that enhance decision-making, case preparation, and litigation strategy. Designed for legal professionals, it streamlines strategic work like case assessments and motion argument development while automating time-consuming tasks such as motion drafting, client updates, and discovery preparation. These efficiencies free up attorneys to focus on strategic decision-making and client advocacy.

“Trellis is uniquely positioned to support attorneys within the very court system where their cases are filed,” said Nicole Clark, CEO and cofounder of Trellis and a former litigator. “Trellis provides access to hundreds of millions of motions and briefs, representing millions of hours of attorney blood, sweat, and tears in research and drafting. It’s why Trellis AI stands as the only tool to offer one-click solutions to create work product backed by the entire court system and learnings from every trial court litigator who came before them.”

Unlocking New Litigation Strategies
Trellis AI is designed to support every stage of the case lifecycle, delivering impactful work product powered by Trellis’ extensive data. Its feature suite tackles common litigation challenges by automating routine tasks and providing strategic insights grounded in the nation’s most trusted court data.

For example, “Draft Arguments” is a powerful motion drafting tool that can save hours of work, allowing attorneys to focus on their strongest arguments. Trellis AI uses the details and facts of the case to create tailored draft motions, drawing from its extensive database of similar cases to suggest strategic, fact-supported arguments. Each draft incorporates insights from hundreds of thousands of successful trial court motions, offering attorneys an innovative solution that transforms how they approach motion drafting.

Another tool is “Case Assessment” which evaluates key case elements to guide strategic decision-making. Trellis AI examines case facts, legal claims, and defenses to provide detailed insights into potential outcomes, recommended actions, and risk factors. Each assessment delivers actionable intelligence and recommended next steps to inform decisions on case management, settlement strategies, and trial preparation. This empowers attorneys to keep their clients informed, offer strategic recommendations, and leverage an internal knowledge base of strategies and insights for each case.

The remainder of Trellis AI’s tools streamline important tasks like complaint analysis, defense strategy development, argument evaluation, timeline creation, citation extraction, and more. All tools were created and meticulously tested by Trellis’ teams of product attorneys and experienced litigators.

Precision and Security at the Core
Trellis AI is designed for ease-of-use without sacrificing security or accuracy. All uploaded documents are encrypted at rest, aligning with SOC 2 standards to protect sensitive information. Additionally, Trellis AI reduces the risk of errors or bias in its outputs, enabling legal teams to concentrate on insights rather than processes. It also provides options for easy verification and source checking, ensuring greater confidence and peace of mind.

“The potential for AI to transform the legal field depends on the quality and depth of data behind it,” said Alon Shwartz, CPO and cofounder of Trellis. “Our data foundation is the cornerstone of Trellis AI, providing a wealth of high-quality information that drives actionable recommendations and meaningful insights. By prioritizing data integrity and implementing rigorous security measures, we’ve built a platform attorneys can trust to streamline workflows and make strategic decisions confidently.”

For more information, click here to book a demo or to get started with Trellis AI.

About Trellis

About Trellis
Trellis is the leading provider of state trial court data and insights, serving tens of thousands of law firms and litigators daily with insights and coverage across 3,000+ courts in over 2,500 counties, spanning 45 states. Trellis offers an extensive suite of state trial court intelligence and productivity tools for litigators, including detailed judge bios and analytics, thorough case assessments, argument drafting and generation, litigation insights across both law firms and corporations, daily reports on new filings, customizable alerts, and much more. Explore more or book a demo at trellis.law.

CONTACT: Media Contact: Ignacio Ramirez, ignacio@switchpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/trellis-launches-trellis-ai-to-revolutionize-trial-court-litigation-302309536.html

SOURCE Trellis

Continue Reading

Technology

Burkland Launches Dedicated Expert Team to Support AI Startups

Published

on

By

New specialty practice is dedicated to meeting the unique needs of AI startups.

SAN FRANCISCO, Nov. 19, 2024 /PRNewswire-PRWeb/ — Burkland, a full-service fractional CFO, HR, accounting, and tax provider for startups, today announces a new specialty practice team dedicated to meeting the distinct needs of AI startups. Burkland’s experts in accounting, finance, tax, and more are helping these AI companies scale with strategies tailored to their unique challenges.

“A founder’s focus is on building a solution, so this is precisely where Burkland’s fractional support teams can provide much-needed help,” said Jeff Burkland, founder and CEO of Burkland.

“Many of our clients are hard at work creating innovative AI solutions, with these startups using new technology to create even newer technology. A founder’s focus is on building a solution, so this is precisely where Burkland’s fractional support teams can provide much-needed help,” said Jeff Burkland, founder and CEO of Burkland. “There are several key roles like the CFO, accountant, and tax advisor, all of which play critical roles in helping AI startups anticipate and address challenges.”

Due to aspects such as the cutting-edge nature of an AI startup’s technology, rapidly evolving industry landscape, and heavy reliance on data and talent, an AI startup faces a unique set of challenges. Needs include the ability to navigate complex revenue recognition since an AI startup can have multiple revenue streams. Also important is an understanding of R&D tax credits and other tax opportunities, as well as how to manage large funding rounds and the associated due diligence.

“As the founder of a startup, there is a lot of pressure on your shoulders all the time,” said Burkland client Lin Qiao, Co-Founder & CEO of Fireworks AI, on Burkland’s Startup Success podcast. “You’re creating something from scratch that doesn’t exist. If you have a resource to tap into, it will be great because we’re always busy day to day.”

Burkland has served as an important resource for startups, from pre-seed through series C, for more than 20 years. Today, approximately 800 venture-backed startups, across multiple industries, are leveraging Burkland’s expertise. For more information, founders should read “The Smarter Startup” blog, listen to the “Startup Success” podcast, and learn more about Burkland’s fractional services and offerings.

About Burkland

Burkland is a full-service fractional CFO, Accountancy, Tax, and HR provider, serving more than 800 venture-backed startups across the United States. SaaS, AI, Healthcare, Fintech, Clean Energy, and Consumer startups rely on Burkland for smarter finance, accounting, People Operations, and tax guidance to grow with confidence. As a leader in market share in the industry, we pride ourselves on giving startups expertise that makes economic sense for all growth stages, ranging from Pre-Seed to Series C. Our on-demand CFOs, Accountants, People Partners, and Tax Experts give strategic guidance to ease a company’s growing pains and provide insight to scale. Learn more at https://burklandassociates.com.

For media inquiries or further information, please visit Burkland’s press page or contact Julie Fogerson at jfogerson@burklandassociates.com.

Media Contact

Julie Fogerson, Burkland, 1 4255033154, jfogerson@burklandassociates.com, https://burklandassociates.com

View original content to download multimedia:https://www.prweb.com/releases/burkland-launches-dedicated-expert-team-to-support-ai-startups-302308389.html

SOURCE Burkland

Continue Reading

Trending